Sekisui announces Acucy flu test clearance

LabPulse.com staff writers
Oct 8, 2019
2019 10 09 20 17 0927 Influenza Virus 400

Sekisui Diagnostics announced that its Acucy influenza A and B test has received 510(k) clearance and CLIA waiver from the U.S. Food and Drug Administration (FDA).

The test is designed for use with the company's Acucy point-of-care reader, which Sekisui said can be used to test nasal and nasopharyngeal swabs onsite as well as in laboratory settings. Sekisui announced the clearance on October 8, following an FDA decision on December 17, 2018.

Sekisui also markets the Osom Ultra (manual read lateral flow) and Silaris molecular point-of-care tests for influenza A and B.

Latest in Influenza
Lab Virus Bacteria Research Social
Alveo develops rapid test for avian flu
July 23, 2024
Colorized transmission electron micrograph of avian influenza A H5N1 virus particles (yellow), grown in Madin-Darby Canine Kidney (MDCK) epithelial cells (blue). Microscopy by CDC; repositioned and recolored by NIAID.
BARDA awards Moderna $176M for pandemic flu vaccine development
July 2, 2024
Visit our Molecular Diagnostics Community
Sponsored
Visit our Molecular Diagnostics Community
April 5, 2024
Vaccine Injection Woman Social
Moderna’s mRNA flu shot yields promising results in phase III trial
September 15, 2023
Related Stories
2020 06 09 23 04 8474 Seksui Osom Ultra Plus Flu Test (1) 400
Influenza
Sekisui secures FDA clearance, CLIA waiver for rapid flu antigen test
2019 10 22 23 43 4032 Influenza Virus Cdc 400
CE mark
BioGX's expanded flu/RSV test gets CE-IVD Mark
2019 09 13 20 38 3693 Respiratory Syncytial Virus Cdc 400
Influenza
Applied BioCode files 510(k) for respiratory panel
Visit our Molecular Diagnostics Community
Sponsor Content
Visit our Molecular Diagnostics Community
More in Influenza
Alveo develops rapid test for avian flu
By LabPulse.com staff writers
Diagnostics firm Alveo Technologies has developed a rapid, point-of-need diagnostic for avian influenza that can detect the H5N1 variant based on sequences published from recent human and cattle infections.
July 23, 2024
Lab Virus Bacteria Research Social
BARDA awards Moderna $176M for pandemic flu vaccine development
By LabPulse.com staff writers
The Biomedical Advanced Research and Development Authority (BARDA) has awarded Moderna approximately $176 million for the development of an mRNA-based pandemic influenza vaccine.
July 2, 2024
Colorized transmission electron micrograph of avian influenza A H5N1 virus particles (yellow), grown in Madin-Darby Canine Kidney (MDCK) epithelial cells (blue). Microscopy by CDC; repositioned and recolored by NIAID.
NIH starts early-phase trial of second-generation universal flu vaccine candidate
By Nick Paul Taylor
The U.S. National Institutes of Health (NIH) has begun an early-phase clinical trial of its second-generation universal flu vaccine candidate.
September 20, 2023
Needle Shot Vaccine Teenager Social
Moderna’s mRNA flu shot yields promising results in phase III trial
By LabPulse.com staff writers
Moderna announced that its mRNA flu shot that is in development has met its primary endpoints in a phase III trial, generating a stronger immune response than a commercially available flu vaccine.
September 15, 2023
Vaccine Injection Woman Social
COVID-19 still associated with higher death risk than flu
By Elissa Wolfson
VA hospital patients with COVID-19 had a higher risk of death than seasonal influenza patients from fall 2022 to winter 2023.
April 11, 2023
Influenza Virus Social
FDA grants 510(k) clearance to DiaSorin for COVID-19 and flu A/B assay
By Leo O'Connor
The test detects and differentiates influenza A, influenza B, and SARS-CoV-2 viruses to help ensure physicians can recommend the most appropriate treatment for each patient.
March 20, 2023
Fda Button Social
Cepheid says its influenza assays mitigate impact of mutational drift seen in some tests
By LabPulse.com staff writers
Two mutations in the matrix genes of the human influenza A virus have been reported to cause matrix gene target failure for several commercial diagnostic tests.
December 8, 2022
Flu Season Ahead Social
Reagent supplier launches antigens for Southern Hemisphere's 2023 flu season
By LabPulse.com staff writers
The hemagglutinin and neuraminidase antigens were developed in response to flu vaccine formulations the World Health Organization selected for development in the Southern Hemisphere.
November 21, 2022
Flu Season Ahead Social
Virax introduces rapid test kit for RSV, influenza A/B, COVID-19
By LabPulse.com staff writers
Virax Biolabs announced the distribution of a rapid antigen test kit capable of detecting when individuals have been infected with RSV, Influenza A/B, or COVID-19.
November 3, 2022
Respiratory Syncytial Virus Cdc Social
University of Illinois spinout Shield T3 launches saliva-based PCR test for COVID, flu, RSV
By LabPulse.com staff writers
Shield T3, a spinout of the University of Illinois, will offer a triple-virus PCR test kit, in anticipation of increased cases of COVID-19, flu, and RSV this winter.
October 25, 2022
Covid Diagnostic Test Kit
Walgreens Flu Index shows 2022-2023 season exhibiting tenfold increase over last year
By LabPulse.com staff writers
The Walgreens Flu Index indicates that flu activity this year is more than 10 times higher than in the previous year and has doubled over the past two weeks.
October 24, 2022
Influenza Virus Cdc
DiaSorin developing point-of-care molecular test for SARS-CoV-2, influenza under BARDA contract
By LabPulse.com staff writers
DiaSorin will develop, verify, and clinically validate a point-of-care instrument and an initial combination test for SARS-CoV-2 and influenza A and B.
October 7, 2022
Influenza Virus
Page 1 of 7
Next Page